Figure 8. Ixazomib therapy induces processing of effector caspases and poly (ADP-ribose) polymerase (PARP).
A. BRAF V600E mutant (A375) human melanoma tumor cells plated at a density of 2 × 105 cells/well on a 6 well plate were treated for 48 hours with complete medium supplemented with either 35 nM ixazomib, 15 nM ixazomib, 10 nM bortezomib, or 10% dimethyl sulfoxide (control). Immunoblots were prepared and probed with antibodies specific for caspase-3, caspase-7, cleaved caspase-7, caspase-8, caspase-9, poly(ADP-ribose) polymerase (PARP), and cleaved PARP. B. A375 tumor cells were treated for 48 hours with IFN-α (104 units/mL), ixazomib (15-65 nM), or both agents combined and evaluated by immunoblot analysis for cleaved caspase-3, caspase-7, and PARP. Membranes were probed with an anti-β-actin antibody as a loading control.